Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + CRT in Resectable Pancreatic Cancer
NCT02305186Phase 2Unknown
- Start
- Mar 2015
- Primary completion
- Dec 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pembrolizumab in pancreatic cancer (PC) (2 arms). Primary endpoints: Tumor Infiltrating Lymphocytes and Dose-Limiting Toxicities. Status: unknown.
02
Drugs
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT02305186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02305186.